Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

AIMS: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. METHODS AND RESULTS: Hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Ferreira, João Pedro, Pocock, Stuart J, Giannetti, Nadia, Januzzi, James L, Piña, Ileana L, Lam, Carolyn S P, Ponikowski, Piotr, Sattar, Naveed, Verma, Subodh, Brueckmann, Martina, Jamal, Waheed, Vedin, Ola, Peil, Barbara, Zeller, Cordula, Zannad, Faiez, Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clnical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014525/
https://www.ncbi.nlm.nih.gov/pubmed/33420498
http://dx.doi.org/10.1093/eurheartj/ehaa1007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014525/
https://www.ncbi.nlm.nih.gov/pubmed/33420498
http://dx.doi.org/10.1093/eurheartj/ehaa1007

Ejemplares similares